https://doi.org/10.4081/aiua.2016.1.74
Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
Submitted: April 11, 2016
Accepted: April 11, 2016
Published: March 31, 2016
Accepted: April 11, 2016
Abstract Views: 1600
PDF: 1100
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
How to Cite
Perletti, G. (2016). Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Archivio Italiano Di Urologia E Andrologia, 88(1), 74–75. https://doi.org/10.4081/aiua.2016.1.74
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Johann de Bono, Liji Shen, Oliver Sartor, Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer , Archivio Italiano di Urologia e Andrologia: Vol. 88 No. 1 (2016)
You may also start an advanced similarity search for this article.